Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X. Gladman DD, et al. Among authors: poddubnyy d. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y. Trials. 2022. PMID: 36064592 Free PMC article.
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J. Song IH, et al. Among authors: poddubnyy d. Ann Rheum Dis. 2013 Jun;72(6):823-5. doi: 10.1136/annrheumdis-2012-202389. Epub 2012 Nov 21. Ann Rheum Dis. 2013. PMID: 23172749 Clinical Trial.
Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.
Pedersen SJ, Poddubnyy D, Sørensen IJ, Loft AG, Hindrup JS, Thamsborg G, Asmussen K, Hendricks O, Nørregaard J, Piil AD, Møller JM, Jurik AG, Balding L, Lambert RG, Sieper J, Østergaard M. Pedersen SJ, et al. Among authors: poddubnyy d. Arthritis Rheumatol. 2016 Feb;68(2):418-29. doi: 10.1002/art.39434. Arthritis Rheumatol. 2016. PMID: 26414004 Clinical Trial.
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.
Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R. Lambert RG, et al. Among authors: poddubnyy d. Ann Rheum Dis. 2016 Nov;75(11):1958-1963. doi: 10.1136/annrheumdis-2015-208642. Epub 2016 Jan 14. Ann Rheum Dis. 2016. PMID: 26768408 Review.
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Smolen JS, et al. Among authors: poddubnyy d. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Ann Rheum Dis. 2018. PMID: 28684559 Free PMC article.
Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.
Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K. Baraliakos X, et al. Among authors: poddubnyy d. J Rheumatol. 2018 Feb;45(2):153-157. doi: 10.3899/jrheum.170222. J Rheumatol. 2018. PMID: 29419447 Free article. No abstract available.
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group. Deodhar A, et al. Among authors: poddubnyy d. Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8. Arthritis Rheumatol. 2019. PMID: 30343531 Free PMC article. Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
259 results